Literature DB >> 9722032

Antithrombin III and sepsis.

E F Mammen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9722032     DOI: 10.1007/s001340050639

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  11 in total

Review 1.  Septic shock: pathogenesis.

Authors:  M P Glauser; G Zanetti; J D Baumgartner; J Cohen
Journal:  Lancet       Date:  1991-09-21       Impact factor: 79.321

Review 2.  Sepsis trials. Intersection of investigation, regulation, funding, and practice.

Authors:  G R Bernard
Journal:  Am J Respir Crit Care Med       Date:  1995-07       Impact factor: 21.405

Review 3.  Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation.

Authors:  M Jochum
Journal:  Semin Hematol       Date:  1995-10       Impact factor: 3.851

4.  Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells.

Authors:  T Yamauchi; F Umeda; T Inoguchi; H Nawata
Journal:  Biochem Biophys Res Commun       Date:  1989-09-29       Impact factor: 3.575

Review 5.  Antithrombin: its physiological importance and role in DIC.

Authors:  E F Mammen
Journal:  Semin Thromb Hemost       Date:  1998       Impact factor: 4.180

Review 6.  The haematological manifestations of sepsis.

Authors:  E F Mammen
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

7.  Time course of hemostatic abnormalities in sepsis and its relation to outcome.

Authors:  J A Lorente; L J García-Frade; L Landín; R de Pablo; C Torrado; E Renes; A García-Avello
Journal:  Chest       Date:  1993-05       Impact factor: 9.410

8.  Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis.

Authors:  R M Mesters; N Flörke; H Ostermann; J Kienast
Journal:  Thromb Haemost       Date:  1996-06       Impact factor: 5.249

9.  Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation.

Authors:  F Fourrier; C Chopin; J J Huart; I Runge; C Caron; J Goudemand
Journal:  Chest       Date:  1993-09       Impact factor: 9.410

Review 10.  The pathogenesis of sepsis.

Authors:  R C Bone
Journal:  Ann Intern Med       Date:  1991-09-15       Impact factor: 25.391

View more
  1 in total

1.  High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats.

Authors:  Satoshi Hagiwara; Hideo Iwasaka; Shigekiyo Matsumoto; Takayuki Noguchi
Journal:  Intensive Care Med       Date:  2007-10-17       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.